The WHO prequalification clears the way for countries and global agencies to procure the medicine for public health programmes, expanding access to a quality-assured treatment for one of the most vulnerable groups. While the immediate impact is expected in high-burden regions such as Africa, the approval also opens the door for countries like India to adopt the formulation through national programmes if needed.
